2/24
04:30 pm
teva
Teva to Present at the Upcoming Investor Conferences in March
Low
Report
Teva to Present at the Upcoming Investor Conferences in March
2/20
07:12 pm
teva
Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
2/20
03:37 pm
teva
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Low
Report
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
2/20
02:43 pm
teva
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Low
Report
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
2/19
04:02 pm
teva
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals [Yahoo! Finance]
Low
Report
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals [Yahoo! Finance]
2/19
11:11 am
teva
Corcept falls as appeals court sides with Teva in Korlym patent dispute [Seeking Alpha]
Low
Report
Corcept falls as appeals court sides with Teva in Korlym patent dispute [Seeking Alpha]
2/18
10:42 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
2/17
06:00 am
teva
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Low
Report
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
2/14
07:09 pm
teva
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is largely controlled by institutional shareholders who own 74% of the company [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is largely controlled by institutional shareholders who own 74% of the company [Yahoo! Finance]
2/9
12:54 pm
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $45.00. They now have a "buy" rating on the stock.
2/6
08:11 am
teva
Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential? [Yahoo! Finance]
Low
Report
Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential? [Yahoo! Finance]
2/4
09:28 am
teva
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat [Yahoo! Finance]
Medium
Report
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat [Yahoo! Finance]
2/3
09:42 pm
teva
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]
1/31
07:03 pm
teva
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]
Medium
Report
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]
1/31
09:57 am
teva
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]
Medium
Report
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]
1/31
01:33 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at
W
Medium
Report
Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at
W
1/30
07:12 pm
teva
Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]
Medium
Report
Does Teva's Return To Profitability And Branded-Drug Shift Reshape The Bull Case For TEVA? [Yahoo! Finance]
1/30
11:38 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an "overweight" rating on the stock.
1/29
10:35 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a "buy" rating on the stock.
1/29
10:35 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Scotiabank from $35.00 to $40.00. They now have a "sector outperform" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Scotiabank from $35.00 to $40.00. They now have a "sector outperform" rating on the stock.
1/29
12:23 am
teva
Teva Pharmaceutical Industries Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries Q4 Earnings Call Highlights [Yahoo! Finance]
1/28
08:27 am
teva
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) [Yahoo! Finance]
Medium
Report
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) [Yahoo! Finance]
1/28
07:38 am
teva
Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast [Seeking Alpha]
Medium
Report
Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast [Seeking Alpha]
1/28
07:00 am
teva
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Low
Report
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
1/28
05:13 am
teva
Pharma Data Integrity Auditor Masterclass Training Course: Department-Level Audit Strategies, Critical Findings, and Regulatory Expectations (Online Event: Apr 22nd - Apr 23rd, 2026) [Yahoo! Finance]
Low
Report
Pharma Data Integrity Auditor Masterclass Training Course: Department-Level Audit Strategies, Critical Findings, and Regulatory Expectations (Online Event: Apr 22nd - Apr 23rd, 2026) [Yahoo! Finance]